IRLAB Therapeutics has announced that a drug candidate has been nominated from the P003 research project.
The drug candidate, IRL1117, will be developed as a once-daily oral treatment for the hallmark symptoms of Parkinson’s without inducing the troublesome complications caused by today’s mainstay anti-Parkinson’s levodopa treatments, states the company.
Initiation of development towards clinical studies has commenced and IRL1117 is expected to start Phase I studies in 2024.
“IRL1117 is an orally available and potent dopamine D1 and D2 receptor agonist that has demonstrated rapid onset and more than 10 hours of sustained efficacy in preclinical studies. This is a sharp contrast to the short duration of today’s Parkinson’s treatment alternatives, thus indicating that IRL1117 could become a significant improvement in the treatment of Parkinson’s. We see tremendous potential in IRL1117, and its follow-on compounds, already at the initial stages of preclinical development and we are looking forward to learning more about the efficacy and safety profile of IRL1117 as it develops toward clinical studies,” said Nicholas Waters, EVP and Head of R&D, IRLAB.
Photo of Nicholas Waters: IRLAB